Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Autor: Garcia-Gutierrez, Valentin, Luna, Alejandro, Alonso-Dominguez, Juan M., Estrada Barreras, Natalia, Boque, Concepcion, Xicoy, Blanca, Giraldo, Pilar, Angona, Anna, Álvarez Larrán, Alberto, Sanchez-Guijo, Fermin, Ramírez, María José, Mora, Elvira, Vélez, Patricia, Rosell, Ana, Colorado Araujo, Mercedes, Cuevas, Beatriz, Sagüés, Miguel, Cortés, Montserrat, Pérez Encinas, Manuel, Casado Montero, Luis Felipe, Moreno Vega, Melania, Serrano, Luis, Gomez, Valle, Garcia-Hernandez, Carmen, Lakhwani, Sunil, Paz Coll, Antonio, De Paz, Raquel, Suarez-Varela, Sara, Fernandez-Ruiz, Andrés, Perez Lopez, Raul, Ortiz-Fernández, Almudena, Jiménez-Velasco, Antonio, Steegmann-Olmedillas, Juan Luis, Hernandez-Boluda, Juan Carlos, Universitat Autònoma de Barcelona
Přispěvatelé: [Garcia-Gutiérrez V, Luna A] Hematology, Hospital Universitario Ramón y Cajal. IRYCIS, Madrid, Spain. [Alonso-Dominguez JM] Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), UAM, Madrid, Spain. [Estrada N, Xicoy B] Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain. [Boque C] Institut Català d’Oncologia – L’Hospitalet de Llobregat, L’Hospitalet de Llobregat, Spain. [Cortes M] Hospital General de Granollers, Granollers, Spain, Departament de Salut
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Adult
Male
Niacinamide
medicine.medical_specialty
Heterocyclic Compounds::Acids
Heterocyclic::Nicotinic Acids::Niacinamide [CHEMICALS AND DRUGS]
MEDLINE
Fusion Proteins
bcr-abl
Drug development
Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia
Myelogenous
Chronic
BCR-ABL Positive [DISEASES]
lcsh:RC254-282
Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors [CHEMICALS AND DRUGS]
Young Adult
Text mining
Leukemia
Myelogenous
Chronic
BCR-ABL Positive
hemic and lymphatic diseases
Correspondence
compuestos heterocíclicos::ácidos heterocíclicos::ácidos nicotínicos::niacinamida [COMPUESTOS QUÍMICOS Y DROGAS]
Medicine
In real life
Humans
Intensive care medicine
Protein Kinase Inhibitors
Aged
Aged
80 and over
Leucèmia mieloide crònica - Tractament
business.industry
acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas [COMPUESTOS QUÍMICOS Y DROGAS]
Myeloid leukemia
Hematology
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Tiroxina - Inhibidors
Clinical Practice
Treatment Outcome
Oncology
Molecularly targeted therapy
Proteïna quinasa CK2
Pyrazoles
Female
enfermedades hematológicas y linfáticas::enfermedades hematológicas::enfermedades de la médula ósea::trastornos mieloproliferativos::leucemia mielogenosa crónica BCR-ABL positiva [ENFERMEDADES]
business
Zdroj: Scientia
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-4 (2021)
BLOOD CANCER JOURNAL
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Blood Cancer Journal
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
ISSN: 2044-5385
Popis: Chronic myeloid leukemia; Asciminib; Treatment Leucemia mieloide crónica; Asciminib; Tratamiento Leucèmia mieloide crònica; Asciminib; Tractament Despite the excellent overall survival (OS) of chronic myeloid leukemia (CML) patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) due to resistance or intolerance. Intolerant patients are usually managed successfully with alternative second-generation tyrosine-kinase inhibitors (2GTKIs). However, more than half of the patients will eventually discontinue second-line treatment due to loss of response or toxicity. Ponatinib is an effective drug in the setting of resistance to 2GTKIs, however with life-threatening side effects and varying responses. Asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor that potently and specifically inhibits BCR-ABL1 via binding to a pocket distinct from the ATP binding site of the kinase. Asciminib has the potential to overcome resistance to prior TKIs, and also offers the possibility of dual inhibition of BCR-ABL1 in combination with ATP-binding TKIs. Asciminib has been evaluated in a phase I study in patients with Ph-positive leukemia failing prior TKIs, with promising results. Our aim is to share the first data on the use of asciminib in CML patients in clinical practice, allowed by Novartis under a managed-access program (MAP).
Databáze: OpenAIRE
Externí odkaz: